Articles from The Wistar Institute

Philadelphia-led consortium is selected to tailor HIV curative strategies to participant

Researchers’ Discovery Leads to Effective Anti-Tumor Treatment in Lab Testing

Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and Chamber of Commerce for Greater Philadelphia Launch Second Recruitment for Award-Winning Program on August 22

Findings show potential for new lipid-based delivery formulations as a platform technology for immunization

PHILADELPHIA, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The lab of The Wistar Institute’s Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper, “Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma,” from the journal Science Translational Medicine.

Trispecific Design Controls Glioblastoma Tumors in Preclinical Models

Demonstrates Novel Combination of Beta Glucan and Interferon Gamma Results in Tumor Regression

Wistar’s Altieri lab uncovered the protein’s powerful influence on immune response to tumors.

Center Headquartered at New Wistar North Campus

PHILADELPHIA, PA, May 14, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA — (May 14, 2024) — The Wistar Institute was awarded a $649,971 grant from the National Science Foundation (NSF) to support the continued expansion of its award-winning Biomedical Technician Training (BTT) Pre-apprenticeship Program.  The grant supports Wistar’s reach to community colleges in New Jersey and Delaware who may have limited or no access to hands-on laboratory training and internships. This marks the second NSF grant supporting the Program’s continued expansion. 

Geneos Therapeutics, Wistar, and Collaborators Translate Personalized DNA Vaccine Technology into Clinical Outcome Based on Mistakes Tumors Make

PHILADELPHIA, PA, March 20, 2024 (GLOBE NEWSWIRE) -- Marking the next step in their innovative academic collaboration, Philadelphia College of Osteopathic Medicine (PCOM) and The Wistar Institute have announced the launch of a highly anticipated Cancer Biology Ph.D. Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer."This announcement signifies a pivotal moment in our collaboration with Wistar, and a continuation of our commitment to offer world-class medical education and research,” said PCOM President and CEO Jay S. Feldstein, DO. “Together, with the expertise and resources of Wistar combined with the academic excellence of PCOM, we will continue to push the boundaries of scientific knowledge to confront the complexities of cancer and improve outcomes for patients everywhere.”“Our hope is that by harnessing the collective expertise of PCOM’s esteemed faculty and the renowned researchers at Wistar, we can accelerate discoveries, develop innovative therapies, and, ultimately, bring hope to those affected by cancer,” said Gregory McDonald, DO, dean of the School of Health Sciences at PCOM. “This collaboration exemplifies our shared dedication to achieving those goals."“This collaboration with PCOM means Philadelphia now has a new biomedical science Ph.D. program to support our region’s growing life science sector. Wistar’s innovative research programs are in lockstep with PCOM’s new life science sector degree program,” said Dario C. Altieri, M.D., Wistar President and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor.

Novel human Siglec-7 monoclonal and bispecific antibodies are being developed as potential future cancer immunotherapies

Wistar Institute, West Philadelphia Skills Initiative, PIDC, and Chamber of Commerce for Greater Philadelphia Announce VintaBio as New Employer Partner

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio. In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC. In evaluating EBVaGC’s epigenetics — the series of biological signals associated with the genome that determines whether a given gene is expressed — the Tempera lab highlights a target that could advance as a future treatment for this type of cancer.

Wistar scientists propose more equitable, collaborative standard to advance HIV cure-directed research

PHILADELPHIA, PA, July 26, 2023 (GLOBE NEWSWIRE) -- It’s been known since the 1960s that Epstein-Barr Virus (EBV) causes a variety of cancers, but research has overwhelmingly focused on its connection to lymphomas. Now, a multidisciplinary team of scientists led by The Wistar Institute has been awarded a more than $12 million National Cancer Institute (NCI) Program Project Grant (P01), a highly competitive five-year grant that includes a crosssection of researchers from various disciplines and institutions throughout the country. The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers. Epithethelial cells form functional structures in organ tissue throughout the human body; they are often the site for solid organ cancers, including the most common cancers, which are known as carcinomas.